# Preventing Structural Damage in Early Psoriatic Arthritis

> **NCT07486843** · PHASE4 · RECRUITING · sponsor: **Chinese University of Hong Kong** · enrollment: 108 (estimated)

## Conditions studied

- Psoriatic Arthritis (PsA)

## Interventions

- **DRUG:** Amgevita 40Mg Solution for Injection
- **DRUG:** Methotrexate (Metoject® prefilled pen)

## Key facts

- **NCT ID:** NCT07486843
- **Lead sponsor:** Chinese University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-16
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 108 (ESTIMATED)
- **Last updated:** 2026-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07486843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07486843, "Preventing Structural Damage in Early Psoriatic Arthritis". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT07486843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*